G2-M DNA damage checkpoint

DEBIOPHARM ANNOUNCES ONCOLOGY RESEARCH ADVANCEMENTS AT AACR 2022 FOR NOVEL CANCER COMPOUNDS AND DRUG DELIVERY TECHNOLOGIES

Retrieved on: 
월요일, 4월 11, 2022
LA, Cell, Company, DAR, Cell cycle, Therapy, Debiopharm, DNA, Neck, CRT, III, DNA repair, Chemoradiotherapy, S phase, Research, Head, G1 phase, WEE1, IAPS, Neurological disorder, Apoptosis, Control, Technology, Safety, G2-M DNA damage checkpoint, Patient, Infection, Vaccine, Pharmaceutical industry, Genome, Merck

LAUSANNE, Switzerland, April 11, 2022 /PRNewswire/ -- Debiopharm, (www.debiopharm.com/debiopharm-international/) an oncology and infectious disease focused biopharmaceutical company based in Switzerland, today announced data releases on 3 investigational products including Debio 0123 (Selective WEE1 inhibitor), clinical exploratory results for xevinapant (IAP inhibitor), and 2 Multilink™ technology posters (antibody drug conjugate linker) at the 2022 Annual American Association for Cancer Research (AACR) meeting in New Orleans, Louisiana. The AACR conference serves as the focal point of the cancer research community to gather together and share advances in oncology science. Debiopharm and their partners' poster presentations represent scientific progress in the research of these compounds leveraging novel modes of action and new delivery methods in development to treat cancer types with high unmet needs.

Key Points: 
  • WEE1 inhibition, particularly in combination with DNA damaging agents, induces DNA breaks leading to the accumulation of DNA damage.
  • This highly effective and well-tolerated linker platform is available for use of other specialty biotech or pharmaceutical companies to generate a proprietary, clinical-stage ADCs.
  • In preclinical studies, xevinapant restored sensitivity to apoptosis in cancer cells, thereby depriving them of one of their major resistance mechanisms to anticancer therapy.
  • Since its establishment in 2015, Genome and Company develops next waves of innovative drugs including anti-cancer microbiome therapeutics and novel target immune checkpoint inhibitors.

DEBIOPHARM ANNOUNCES ONCOLOGY RESEARCH ADVANCEMENTS AT AACR 2022 FOR NOVEL CANCER COMPOUNDS AND DRUG DELIVERY TECHNOLOGIES

Retrieved on: 
월요일, 4월 11, 2022
LA, Cell, Company, DAR, Cell cycle, Therapy, Debiopharm, DNA, Neck, CRT, III, DNA repair, Chemoradiotherapy, S phase, Research, Head, G1 phase, WEE1, IAPS, Neurological disorder, Apoptosis, Control, Technology, Safety, G2-M DNA damage checkpoint, Patient, Infection, Vaccine, Pharmaceutical industry, Genome, Merck

LAUSANNE, Switzerland, April 11, 2022 /PRNewswire/ -- Debiopharm, (www.debiopharm.com/debiopharm-international/) an oncology and infectious disease focused biopharmaceutical company based in Switzerland, today announced data releases on 3 investigational products including Debio 0123 (Selective WEE1 inhibitor), clinical exploratory results for xevinapant (IAP inhibitor), and 2 Multilink™ technology posters (antibody drug conjugate linker) at the 2022 Annual American Association for Cancer Research (AACR) meeting in New Orleans, Louisiana. The AACR conference serves as the focal point of the cancer research community to gather together and share advances in oncology science. Debiopharm and their partners' poster presentations represent scientific progress in the research of these compounds leveraging novel modes of action and new delivery methods in development to treat cancer types with high unmet needs.

Key Points: 
  • WEE1 inhibition, particularly in combination with DNA damaging agents, induces DNA breaks leading to the accumulation of DNA damage.
  • This highly effective and well-tolerated linker platform is available for use of other specialty biotech or pharmaceutical companies to generate a proprietary, clinical-stage ADCs.
  • In preclinical studies, xevinapant restored sensitivity to apoptosis in cancer cells, thereby depriving them of one of their major resistance mechanisms to anticancer therapy.
  • Since its establishment in 2015, Genome and Company develops next waves of innovative drugs including anti-cancer microbiome therapeutics and novel target immune checkpoint inhibitors.

XRad Therapeutics Announces First Patient Dosed in Phase 1a Clinical Trial of XRD-0394 for Metastatic, Locally-Advanced or Recurrent Solid Tumors

Retrieved on: 
수요일, 8월 25, 2021
Stanford Cancer Institute, ATM, Memorial Sloan Kettering Cancer Center, Cancer, GLOBE, G2-M DNA damage checkpoint, DNA, Trial of the century, DNA repair, Doctor of Philosophy, Therapy, Safety, RT, PARP, Patient, Control, Pharmaceutical industry, Medical imaging

DURHAM, N.C., Aug. 25, 2021 (GLOBE NEWSWIRE) -- XRad Therapeutics, a privately-held, clinical stage biopharmaceutical company focused on developing dual kinase inhibitors for treating cancer, today announced that the first patient has been dosed in the company’s Phase 1a trial evaluating XRD-0394 in combination with radiation therapy (RT) for the treatment of metastatic, locally-advanced or recurrent solid tumors. XRD-0394 is a first-in-class, oral, dual kinase inhibitor of both ataxia-telangiectasia mutated (ATM) and DNA-dependent protein kinase (DNA-PK) and based on preclinical studies is designed to enhance the effectiveness of radiation therapies.

Key Points: 
  • More than 50% of cancer patients receive radiation therapy as part of their treatment regimen.
  • Despite its widespread use, high unmet needs still exist in many tumor types, said Tona Gilmer, PhD, president, chief executive officer and co-founder of XRad.
  • We look forward to continuing the development of XRD-0394 as we transition into clinical trials.
  • XRad Therapeutics is a privately-held, clinical stage biopharmaceutical company focused on developing dual kinase inhibitors for treating cancer.

Zentalis Pharmaceuticals Announces FDA Clearance of the IND for Its Third Oncology Drug Candidate, ZN-c3, a WEE1 Inhibitor, and the Dosing of the First Patient in a Phase 1/2 Clinical Trial

Retrieved on: 
수요일, 12월 18, 2019
Research, FDA, Clinical trials, Biotechnology, Health, General Health, Other Science, Science, Oncology, Branches of biology, Cell Cycle, Biology, Cell biology, Wee1, PARP inhibitor, Cell cycle checkpoint, DNA replication, G2-M DNA damage checkpoint, Adavosertib

The Company is developing ZN-c3, an oral small molecule DNA Damage Response (DDR) drug candidate targeting WEE1 in cancer settings.

Key Points: 
  • The Company is developing ZN-c3, an oral small molecule DNA Damage Response (DDR) drug candidate targeting WEE1 in cancer settings.
  • WEE1 is a protein tyrosine kinase that regulates the cell cycle by serving as a checkpoint preventing DNA replication in the presence of DNA damage.
  • We believe these characteristics will provide for a differentiated drug product to help fight cancer, if ZN-c3 is approved.
  • The Company is evaluating the potential of ZN-c3 in a Phase 1/2 clinical trial as monotherapy and in combination with an FDA-approved PARP inhibitor.